Cargando…
Tocilizumab: Bowel perforation following off-label use: 2 case reports
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256982/ http://dx.doi.org/10.1007/s40278-021-98577-x |
Ejemplares similares
-
Methylprednisolone/tocilizumab: Intestinal perforation following off-label use: case report
Publicado: (2021) -
Methylprednisolone/tocilizumab: Gastrointestinal perforation following off label use: case report
Publicado: (2021) -
Methylprednisolone/tocilizumab: Intestinal perforation following off-label use: case report
Publicado: (2020) -
Epoprostenol/hydroxychloroquine/tocilizumab: Acute large bowel perforation, off-label use and lack of efficacy: case report
Publicado: (2020) -
Tocilizumab: Acute terminal ileum and perforated caecal ulceration following off label use: case report
Publicado: (2020)